Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week vs 2 times/week Primary: investigator‐rated good/excellent control of symptoms · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks… Interventions for hand eczema (2019) · Cochrane | RR 1.23 [0.94, 1.61] | 1 study · 72 participants | Low |
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week vs 2 times/week Primary: participant‐rated good/excellent control of symptoms Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks… Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week vs 2 times/week Primary: adverse events · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks… Interventions for hand eczema (2019) · Cochrane | RR 1.76 [0.45, 6.83] | 1 study · 72 participants | Low |
Oral methotrexate and oral prednisone vs placebo and oral prednisone Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and… Interventions for morphea (2019) · Cochrane | RR 2.31 [1.2, 4.45] | 1 study · 70 participants | Low |
Narrowband UVB phototherapy vs medium‐dose UVA‐1 phototherapy (50 J/cm²) Primary outcome: Adverse effects · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | RR 0.03 [0, 0.42] | 1 study · 35 participants | Low |
Narrowband UVB phototherapy vs medium‐dose UVA‐1 phototherapy (50 J/cm²) Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | 1 study · 28 participants | Low |
Narrowband UVB phototherapy vs medium‐dose UVA‐1 phototherapy (50 J/cm²) Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | NR | No studies |
Narrowband UVB phototherapy vs low‐dose UVA‐1 phototherapy (20 J/cm²) Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | 1 study · 45 participants | Low |
Narrowband UVB phototherapy vs low‐dose UVA‐1 phototherapy (20 J/cm²) Primary outcome: Adverse effects · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | RR 0.03 [0, 0.41] | 1 study · 45 participants | Low |
Narrowband UVB phototherapy vs low‐dose UVA‐1 phototherapy (20 J/cm²) Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | 1 study · 32 participants | Very low |
Narrowband UVB phototherapy vs low‐dose UVA‐1 phototherapy (20 J/cm²) Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate and oral prednisone vs placebo and oral prednisone Primary outcome: Adverse effects · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and… Interventions for morphea (2019) · Cochrane | RR 1.23 [0.75, 2.04] | 1 study · 70 participants | Low |
Oral methotrexate and oral prednisone vs placebo and oral prednisone Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and… Interventions for morphea (2019) · Cochrane | no estimate extracted | 1 study · 70 participants | Low |
Oral methotrexate and oral prednisone vs placebo and oral prednisone Secondary outcome: Improvement of disease damage · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and… Interventions for morphea (2019) · Cochrane | no estimate extracted | 1 study · 70 participants | Ungraded |
Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²) Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | 1 study · 44 participants | Low |
Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²) Primary outcome: Adverse effects · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | RR 1 [0.91, 1.1] | 1 study · 44 participants | Low |
Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²) Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | 1 study · 36 participants | Low |
Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²) Secondary outcome: Improvement of disease damage ‒ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | NR | No studies |
Narrowband UVB phototherapy vs medium‐dose UVA‐1 phototherapy (50 J/cm²) Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | 1 study · 35 participants | Low |
Clarithromycin vs placebo The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin vs placebo Reduction in itch score within 2 weeks as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 1 study · 34 participants | Moderate |
Erythromycin vs placebo The proportion of participants with good or excellent rash improvement within 2 weeks as rated by a medical practitioner · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 4.02 [0.28, 56.61] | 2 studies · 86 participants | Low |
Erythromycin vs placebo Minor participant‐reported adverse events not requiring withdrawal of the treatment: Gastrointestinal upset. · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 2 [0.2, 20.04] | 1 study · 34 participants | Moderate |
Azithromycin vs placebo or vitamins The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs placebo or vitamins Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 2 studies · 119 participants | Moderate |
Azithromycin vs placebo or vitamins The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 0.83 [0.28, 2.48] | 1 study · 70 participants | Moderate |
Azithromycin vs placebo or vitamins Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 1 study · 70 participants | Moderate |
Azithromycin vs placebo or vitamins The proportion of participants with good or excellent rash improvement within 2 weeks as rated by a medical practitioner. · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 1.02 [0.52, 2] | 2 studies · 119 participants | Low |
Azithromycin vs placebo or vitamins Minor participant‐reported adverse events not requiring withdrawal of the treatment: Mild abdominal pain. · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 5.82 [0.72, 47.1] | 2 studies · 119 participants | Moderate |
Acyclovir vs placebo, vitamins, or no treatment The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Clarithromycin vs placebo Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 1 study · 60 participants | Moderate |
Acyclovir vs placebo, vitamins, or no treatment Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 3 studies · 141 participants | Moderate |
Acyclovir vs placebo, vitamins, or no treatment Proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 0.34 [0.12, 0.94] | 1 study · 21 participants | Moderate |
Acyclovir vs placebo, vitamins, or no treatment Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir vs placebo, vitamins, or no treatment The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 2.45 [1.33, 4.53] | 3 studies · 141 participants | Moderate |
Acyclovir vs placebo, vitamins, or no treatment Minor participant‐reported adverse events not requiring withdrawal of the treatment · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 0.31 [0.01, 7.02] | 3 studies · 141 participants | Moderate |
Acyclovir + calamine + cetirizine vs calamine + cetirizine The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir + calamine + cetirizine vs calamine + cetirizine Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 1 study · 24 participants | Low |
Acyclovir + calamine + cetirizine vs calamine + cetirizine The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 4.5 [1.22, 16.62] | 1 study · 24 participants | Low |
Acyclovir + calamine + cetirizine vs calamine + cetirizine Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 1 study · 24 participants | Low |
Acyclovir + calamine + cetirizine vs calamine + cetirizine The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Clarithromycin vs placebo The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 0.84 [0.47, 1.52] | 1 study · 28 participants | Moderate |
Acyclovir + calamine + cetirizine vs calamine + cetirizine Minor participant‐reported adverse events not requiring withdrawal of the treatment: Headache. · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 7 [0.4, 122.44] | 1 study · 24 participants | Low |
Acyclovir vs erythromycin The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir vs erythromycin Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 1 study · 30 participants | Moderate |
Acyclovir vs erythromycin The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | RR 13.22 [0.91, 192.02] | 1 study · 14 participants | Low |
Acyclovir vs erythromycin Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir vs erythromycin The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Acyclovir vs erythromycin Minor participant‐reported adverse events not requiring withdrawal of the treatment · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Clarithromycin vs placebo Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |